How large pharma impacts biotechnology startup success thumbnail

How large pharma impacts biotechnology startup success

Implications for bioentrepreneurs.

References

  1. 1.

    Geilinger, U. & Bujak, E. 2019 HBM New Drug Approval Report. https://www.hbmpartners.com/en/news-research/?pageIdd55d7643=4#tab_d858312ec47cb6a64ac33daec0044371_3 (2019).

  2. 2.

    Schuhmacher, A., Gassmann, O. & Hinder, M. J. Transl. Med. 14, 105–116 (2016).

    Article 

    Google Scholar
     

  3. 3.

    Senior, M. Nat. Biotechnol. 36, 291–292 (2018).

    CAS 
    Article 

    Google Scholar
     

  4. 4.

    Chin, M. H. W., Gentleman, E., Coppens, M.-O. & Day, E. M. Trends Biotechnol. 38, 1054–1065 (2020).

    Article 

    Google Scholar
     

  5. 5.

    Christel, M. Pharmaceutical Executive 39 (6), 12–23 (2019).


    Google Scholar
     

  6. 6.

    Rooswinkel, R. W., Berbers, D. S. W., Claassen, E. H. J. H. M. & van Deventer, S. Nat. Biotechnol. 34, 1095–1098 (2016).

    CAS 
    Article 

    Google Scholar
     

Download references

Author information

Affiliations

  1. BioGeneration Ventures (BGV), Naarden, the Netherlands

    Gina Melchner von Dydiowa & Daniela S. Couto

  2. Forbion Capital Partners, Naarden, the Netherlands

    Sander van Deventer

Corresponding author

Correspondence to
Daniela S. Couto.

Ethics declarations

Competing interests

G.M.v.D. and D.S.C. are employed by BioGeneration Ventures and S.v.D. is employed by Forbion Capital Partners. These companies invest in biotech ventures.

Supplementary information

About this article

Verify currency and authenticity via CrossMark

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *